{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Spinal+and+Bulbar+Muscular+Atrophy&page=2",
    "query": {
      "condition": "Spinal and Bulbar Muscular Atrophy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Spinal+and+Bulbar+Muscular+Atrophy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T19:53:57.637Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06501911",
      "title": "A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Glioblastoma",
        "Recurrent High-grade Glioma"
      ],
      "interventions": [
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "Intensity-modulated radiation therapy (IMRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-04-08",
      "completion_date": "2025-07-17",
      "has_results": false,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-07-22T19:53:57.637Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06501911"
    },
    {
      "nct_id": "NCT04530500",
      "title": "COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Covid19",
        "Androgen Receptor Gene Overexpression"
      ],
      "interventions": [
        {
          "name": "COVID-19 Androgen Sensitivity Test (CoVAST)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "MALE",
        "summary": "18 Years to 90 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2020-08-13",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-07-22T19:53:57.637Z",
      "location_count": 2,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04530500"
    },
    {
      "nct_id": "NCT01369901",
      "title": "Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Motor Neuron Disease"
      ],
      "interventions": [
        {
          "name": "A functional exercise program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "A stretching exercise program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "MALE",
        "summary": "18 Years to 90 Years · Male only"
      },
      "enrollment_count": 61,
      "start_date": "2011-06-08",
      "completion_date": "2018-02-28",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-07-22T19:53:57.637Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369901"
    },
    {
      "nct_id": "NCT05647564",
      "title": "PET/CT Characterization of Treatment Resistance",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "F-fluorodeoxyglucose positron emission tomography (FDG PET)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "prostate-specific membrane antigen positron emission tomography (PSMA PET)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2023-03-06",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-07-22T19:53:57.637Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05647564"
    },
    {
      "nct_id": "NCT04689828",
      "title": "177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "177Lu-PSMA-617",
          "type": "DRUG"
        },
        {
          "name": "68Ga-PSMA-11",
          "type": "DRUG"
        },
        {
          "name": "ARDT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 469,
      "start_date": "2021-06-15",
      "completion_date": "2026-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-07-22T19:53:57.637Z",
      "location_count": 20,
      "location_summary": "Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04689828"
    },
    {
      "nct_id": "NCT05849298",
      "title": "A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasm"
      ],
      "interventions": [
        {
          "name": "AAA617",
          "type": "DRUG"
        },
        {
          "name": "AAA517",
          "type": "DRUG"
        },
        {
          "name": "Piflufolastat F 18",
          "type": "DRUG"
        },
        {
          "name": "ARPI",
          "type": "DRUG"
        },
        {
          "name": "ADT",
          "type": "DRUG"
        },
        {
          "name": "Best supportive care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 49,
      "start_date": "2024-01-03",
      "completion_date": "2026-12-23",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-07-22T19:53:57.637Z",
      "location_count": 11,
      "location_summary": "Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 8 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05849298"
    },
    {
      "nct_id": "NCT04573231",
      "title": "Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "HER2-negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "18F-DCFPyL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-05-24",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-07-22T19:53:57.637Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04573231"
    },
    {
      "nct_id": "NCT03300505",
      "title": "ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ARRx",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2019-05-31",
      "completion_date": "2023-01-24",
      "has_results": true,
      "last_update_posted_date": "2025-05-13",
      "last_synced_at": "2026-07-22T19:53:57.637Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Detroit, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03300505"
    },
    {
      "nct_id": "NCT07016399",
      "title": "Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Breast Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Epirubicin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Ultrasound Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Vandana Abramson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2025-09-09",
      "completion_date": "2033-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-07-22T19:53:57.637Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07016399"
    },
    {
      "nct_id": "NCT07190300",
      "title": "TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
      ],
      "interventions": [
        {
          "name": "Tulmimetostat",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 181,
      "start_date": "2026-01-13",
      "completion_date": "2032-08-02",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-07-22T19:53:57.637Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07190300"
    }
  ]
}